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Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) poses an increasingly large disease and economic
burden worldwide. The effectiveness of screening programs in the tropics is poorly understood. The aims of this study
are: (i) to analyze the factors affecting MRSA colonization at admission and acquisition during hospitalization and (ii) to
evaluate the cost-effectiveness of a screening program which aims to control MRSA incidence during hospitalization.
Methods: We conducted a retrospective case–control study of patients admitted to the Communicable Disease
Centre (CDC) in Singapore between Jan 2009 and Dec 2010 when there was an ongoing selective screening and
isolation program. Risk factors contributing to MRSA colonization on admission and acquisition during hospital stay
were evaluated using a logistic regression model. In addition, a cost-effectiveness analysis was conducted to determine
the cost per disability-adjusted life year (DALY) averted due to implementing the screening and isolation program.
Results: The average prevalence rate of screened patients at admission and the average acquisition rate at
discharge during the study period were 12.1 and 4.8 % respectively. Logistic regression models showed that older
age (adjusted odds ratio (OR) 1.03, 95 % CI 1.02–1.04, p < 0.001) and dermatological conditions (adjusted OR 1.49,
95 % CI 1.11–1.20, p = 0.008) were independently associated with an increased risk of MRSA colonization at
admission. Age (adjusted OR 1.02, 95 % CI 1.01–1.03, p = 0.002) and length of stay in hospital (adjusted OR 1.04,
95 % CI 1.03–1.06, p < 0.001) were independent factors associated with MRSA acquisition during hospitalization.
The screening and isolation program reduced the acquisition rate by 1.6 % and was found to be cost saving. For
the whole study period, the program cost US$129,916, while it offset hospitalization costs of US$103,869 and loss
of productivity costs of US$50,453 with −400 $/DALY averted.
Discussion: This study is the first to our knowledge that evaluates the cost-effectiveness of screeningand isolation
of MRSA patients in a tropical country. Another unique feature of the analysis is the evaluationof acquisition rates
among specific types of patients (dermatological, HIV and infectious disease patients)and the comparison of the
cost-effectiveness of screening and isolation between them.
Conclusions: Overall our results indicate high MRSA prevalence that can be cost effectively reduced by selective
screening and isolation programs in Singapore.
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Background
Methicillin-resistant Staphylococcus aureus (MRSA) is a
significant cause of nosocomial infection. Once acquired
from a contaminated source, MRSA can lead to asymp-
tomatic colonization or serious infection. The latter has
caused substantial healthcare and economic burden
worldwide. For instance, MRSA-related hospitalizations in
the United States increased more than twofold from 1997
to 2005 [1] and a recent report revealed that there were
over 11,000 MRSA infection related deaths in 2011 http://
www.cdc.gov/drugresistance/threat-report-2013/. In the
European Union, additional hospital stay due to MRSA in-
fection cost hospitals 380 million euros in 2010 [2].
The World Health Organization (WHO) has pub-
lished guidelines and recommendations for prevention
and control of healthcare associated infections includ-
ing MRSA http://whqlibdoc.who.int/publications/2011/
9789241501507_eng.pdf. Various hospitals and countries
have utilized their own practices to suit their needs and
resources for hospital control of MRSA. The Netherlands
has successfully carried out a “search-and-destroy” policy
[3], while the United Kingdom favors targeted screening
and control [4]. The screening method and target popula-
tion are however debatable. Rapid, universal MRSA test-
ing is seemingly ideal but may be expensive and
unwarranted [5]; selective screening, while cost-effective,
may result in missed cases [6].
Cost-effectiveness studies of MRSA control programs
are limited [7, 8]. In USA, it has been shown that screen-
ing programs would present a cost of 19 to 27 times less
than the cost posed by MRSA [9]. Similar results were
found in the Netherlands, Sweden, and France where the
net value of screening and preventive isolation programs
was shown to be positive [10–12]. In Germany, the cost of
treatment and isolation interventions has been shown to
be half the cost of MRSA colonization [13]. In the UK,
screening and decolonization was shown to be robustly
cost-effective to prevalence of MRSA on admission [14].
In Australia, it was shown that peroxide decontamination
reduced MRSA acquisition from 9 to 5.3 per 10,000 pa-
tient days [15, 16]. Cost-benefit analyses in tropical coun-
tries are, however, very rare and it would be useful to
obtain estimates of MRSA prevalence, effectiveness and
cost-effectiveness of screening programs in the tropics to
compare with those in temperate regions.
MRSA is endemic to major hospitals and is among the
most important hospital-acquired pathogens in Singapore
[17, 18], where serious outbreaks have occurred [19, 20].
Incidence and prevalence rates of MRSA have remained
constant over the past two decades in major academic
medical centers. In 2006, a laboratory based surveillance
program of antimicrobial drug-resistance in six public
sector acute-care hospitals in Singapore revealed that
35 % of isolates were MRSA [17]. Among surveyed
Western Pacific countries, this proportion of methicillin
resistance ranged from 23.6 to 73.8 % [21].
Numerous studies have estimated the prevalence of
MRSA at admission to hospitals. In the UK, MRSA
colonization in surgical patients was 5.1 and 6.7 % in
emergency patients. 5.1 % among all patients at a Swiss
teaching hospital [22–24]. There are fewer reports de-
scribing the MRSA colonization status of patients ad-
mitted to Singapore hospitals. In Singapore, MRSA
colonization rate in HIV outpatients and in emergency
patients were 3 and 1.8 % respectively, and Staphylo-
coccus aureus colonization was 23 % [25, 26].
A case–control study conducted at two hospitals in
Singapore found that mortality, length of stay,
hospitalization cost, and losses of quality of life were
associated with MRSA infection [27]. Some other risk
factors such as the presence of co-morbid medical condi-
tion and the use of medical devices have been shown to be
associated with MRSA infections and colonization [28, 29].
An MRSA screening program for selected inpatients
began in January 2009 and is ongoing at the Communic-
able Disease Centre (CDC) at Tan Tock Seng Hospital
(TTSH), which is the primary center for infectious dis-
ease management in Singapore; it also historically
houses patients with dermatological conditions. TTSH is
a 1600-bed adult tertiary-care public hospital with more
than 4500 admissions per month during the study
period. It is also the national referral center for HIV in-
fection and emerging infectious diseases in Singapore.
The program was implemented to determine the MRSA
colonization status of incoming patients and the propor-
tion of inpatients who acquire MRSA during CDC
hospitalization.
The aims of this study are: (i) to analyze the factors af-
fecting MRSA colonization at admission and acquisition
during hospitalization and (ii) to evaluate the cost-
effectiveness of the CDC screening program which aims
to control MRSA incidence during hospitalization.
Methods
Data collection and experimental design
On-going inpatient admissions and discharge screening
for MRSA was conducted during the 24 month study
period (Jan 2009–Dec 2010) in three wards that housed
patients in different categories (1) ward A, HIV (human
immunodeficiency virus) and/or other infectious disease
(ID) patients (patients admitted for dengue fever, mal-
aria, chicken pox, etc.), (2) ward B, dermatological pa-
tients (patients with skin disease) and/or ID patients,
and (3) ward C, HIV patients. Only HIV positive pa-
tients were screened in ward A while all patients in the
other two wards were screened. Ward B is composed of
22 single-bed rooms with attached bathroom and toilet.
The other two have a mixture of single and multi-bed
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rooms. Ward A is structured with 4 single rooms and 12
multi-bed rooms whereas ward C has 9 single rooms with
1 multi-bed room. Each multi-bed room has 2–4 beds.
Upon admission, known MRSA positive patients (pre-
vious known MRSA colonization or infection that was
laboratory confirmed irrespective of time) were isolated
or allocated to cohorts; they were not screened upon
entry or exit. Those who tested positive during initial
screening were isolated and not retested at discharge.
Patients whose MRSA status was negative at entry were
screened upon discharge. Three swabs were taken by
trained health care workers at five sites—one swab for
the nares, axilla, and groin, one for the perianal region,
and one for the throat. Any open wounds were swabbed
as well. Samples were inoculated on chromogenic agar
plates (MRSASelect, BioRad, France) and incubated at
37 °C for 18–28 h. Growth of pink or mauve colonies was
interpreted as MRSA positive, while colorless colonies
were MRSA negative.
MRSA negative patients hospitalized for more than
24 h were swabbed at the same sites upon discharge.
Those who initially tested negative at entry but positive
at exit were determined to have acquired MRSA during
hospitalization. Any MRSA negative patients who were
readmitted to CDC during the study period were re-
screened upon entry and exit, if appropriate.
Demographic data, HIV status, admission discipline
(based on primary diagnosis), ward and MRSA screening
results were collected from medical records of all screened
patients. The costs of the screening program were retro-
spectively collected from hospital administrative databases
where hospital bills were recorded. Interviews with nurse
managers of respective wards who oversee the screening
program were also done to estimate the staff time spent
and the usage of equipment on the various screening activ-
ities and procedures. Data from January 2009 to December
2010 were analyzed. Univariate analysis was used to deter-
mine associations between demographic or hospital admis-
sion with MRSA colonization or acquisition. A chi square
test was used to evaluate differences in categorical variables.
Crude odds ratios (ORs) and 95 % confidence intervals
were calculated for categorical variables. Crude ORs for
continuous variables were obtained by using simple logistic
regression. Stratified analyses for age (> = 65) was used. All
tests were two-tailed, and P values less than 0.05 were
considered statistically significant. All variables with a P
value <0.05 in univariate analysis were included in multi-
variate analyses. A stepwise logistic regression was used to
choose variables that were independently and significantly
associated with MRSA colonization or acquisition and for
inclusion in the final model. A variable was dropped from
the model if it did not reach statistical significance. All
data were analyzed using Stata 9 (Stata Corp., College
Station, TX).
Disease economic burden
The estimated disease burden was calculated for patients
who were detected to be MRSA positive at admission and
progressed to infection. Economic and disease burden in-
clude direct and indirect costs. The direct costs are based
on hospitalization stay while the indirect costs are repre-
sented by the value of productivity loss due to illness-
related absence resulting from additional hospitalization
[30–32]. The direct costs are estimated as the product of
the total average of daily hospital bills of hospital stay due
to MRSA colonization per patient classification (i.e. HIV,
ID, dermatology), the number of patients per classification
and the number of additional hospitalization days per pa-
tient (Table 1). The additional hospitalization days was es-
timated by comparing the length of stay of colonized and
non-colonized patients. In addition, we assumed that 35 %
of the colonized patients will develop infection [33], and
assumed that colonization and infection lead to the same
additional hospitalization.
Using the human capital approach, the indirect costs are
calculated as the product of the gross domestic product
per capita per day, the number of patients per classifica-
tion and the days of work lost due to MRSA colonization
(Table 1).
The screening program cost consists of cost of staff
needed for swab taking including labeling and preparation,
data collection and terminal cleaning of positive rooms,
cost of bottles used for hand rubbing, and the screening
fees paid by patients. The staff cost was calculated by
multiplying staff cost per patient—estimated based on staff
time needed and monthly salary—and number of patients.
Cost of bottles was calculated by multiplying number of
bottles used and cost of one bottle. Screening fees was cal-
culated by multiplying the tariff paid by patient by number
of patients (Table 2). All cost estimates were expressed in
US$ of 2014 (Table 3).
The cost-effectiveness analysis was used to determine the
cost-per-outcome gained. It considers the direct and indir-
ect costs. Disability-adjusted life years (DALYs) due to
MRSA infection were used as an outcome measure for the
cost-effectiveness analysis. DALYs were chosen over other
metrics as quality-adjusted life year (QALYs) because the
WHO recommends that future cost-effectiveness analyses
also use DALYs for purposes of comparability [34]. The fol-
lowing equation outlined by Murray [35] was used to calcu-














where D is the disability weight; r is the social discount
rate; a is the age of the individual at the onset of symp-
toms; L is the duration of the disability; C is the age-
weighting correction constant; and β is the parameter
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from the age-weighting function. The age weighting
function represents the value of life at different ages
(Table 3).
Due to lack of information before implementing the pro-
gram, we used the prevalence of MRSA in the first quarter
of our on-going study period (i.e. Jan 2009–March 2009),
which was estimated at 2.7 %, as a surrogate for MRSA
prevalence if no additional intervention such as de-
colonization of patients was taken; and the last quarter of
our on-going study period (i.e. April–June 2013), which
was estimated at 1.1 %, as a surrogate for MRSA prevalence
with the screening program in place. It is assumed that
this surrogate could reflect the situation before the
program as there is a lag period until the program
could have effect on reducing the MRSA prevalence
rate. The effectiveness of the program in reducing the
MRSA prevalence rate of infected patients was thus as-
sumed to be 1.6 %. The effectiveness was estimated as
the difference between the MRSA prevalence of the
first (Jan–March 2009) and last quarter (April–June 2013)
of our on-going study.
Ethics approval
This study was approved by Domain Specific Review
Board, National Healthcare Group, Singapore (DSRB-
2011/01655).
Table 2 Screening program cost in US$a



















Swabs (entry) 2.74b 913 2504 2.74b 520 1426 2.74b 824 2260
Cleaning (entry) 2.70c 97 262 2.70c 14 38 2.70c 162 438
Collating (entry) 0.55d 913 501 0.55d 520 285 0.55d 824 452
Swabs (discharge) 2.74b 679 1862 2.74b 464 1272 2.74b 624 1711
Collating
(discharge)
0.55d 679 371 0.55d 464 253 0.55d 624 341
Hand rub Bottles 680e 5304 104e 808 1204e 9390
Tariff paid by
patient




aS$ was converted to US$ based on exchange rate of 0.78
bFifteen minutes of staff time is needed to take swabs including labelling/preparation for one patient with a monthly salary of S$2250 [59]
cThirty minutes of staff time is needed to clean MRSA positive room for one patient with a monthly salary of S$950 [59]
dThirty minutes of staff time is needed to collate data for ten patients with a monthly salary of S$2250 [59]
eA bottle cost S$10 (~ US$7.8)
Table 1 Direct and indirect costs avoided by the MRSA screening and isolation program









Hospital bill per day for infectious disease
patient
14 5a 228 4469b
Hospital bill per day for dermatological patient 162 57a 372 63,277c
Hospital bill per day stay for HIV patient 97 34a 226 36,123d
Total direct cost 103,869
Indirect cost
Productivity loss of infectious disease patient 14 5a 155e 2803
Productivity loss of dermatological patient 162 57a 155e 24,324
Productivity loss of HIV patient 97 34a 155e 19,419
Total indirect cost 50,453
aThirty-five percent of the colonized patients are assumed to progress to infection
bBased on four additional hospitalization days and five Infectious disease patients estimated to be progressed to infection
cBased on three additional hospitalization days and 57Dermatological patients estimated to be progressed to infection
dBased on four additional hospitalization days and 34HIV patients estimated to be progressed to infection
eEstimated based on GDP per capita of $US 55,183 [36]
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Results
Statistical analysis
During the study period, of 2476 patient admissions,
2257 patients were screened for MRSA excluding 115
patient admissions with known MRSA status and 104
patient admissions that refused to do screening. Total
number of patient admissions screened from ward A, B
and C were 284, 1591 and 382 respectively. Our data
show that, of these 104 patient admissions that refused
screening on entry, 19 % (20 patients) were screened on
discharge.
Of the 162 MRSA positive screenings from dermato-
logical patients, 21 (13 %) were from wound swabs, com-
pared to only 1 of 111 positive episodes (1 %) among
combined ID and HIV patients. The proportion of pa-
tients fulfilling the screening criteria decreased as the
study period progressed, and the prevalence rate of MRSA
colonization fluctuated. Interestingly, colonization was
lowest in the July–September quarter during both years.
The incidence rate of MRSA acquisition during
hospitalization decreased throughout the study period ex-
cept in the April–June quarter of the second year (Fig. 1).
There was a positive correlation between colonization rate
at admission and acquisition rate at discharge although it
did not reach statistical significance (Spearman’s correlation
coefficient 0.38, p = 0.352).
The average prevalence rate (excluding patients with
known MRSA positive) of screened patients at admission
during the study period was 12.1 %. MRSA colonization
Table 3 Values of parameters used in DALYs
Parameter Value
Age weighting correction constant, C 0.1658a
Social discount rate, r 0. 03a
Average age of the individuals at the onset of symptoms, a 61b
Duration of the disability per year, L 0.01c
Parameter from the age-weighting function, β 0.04a,d
Disability weight, D 0.041e
a[35]
bThe Median age for positive MRSA patients reported in Table 4
cCalculated by dividing addition hospitalization days (i.e. 4 days) by 356 days
dThe age weighting function represents the value of life at different ages. It
reflects the different social roles of individuals at different ages, i.e. young and
elderly require care giving [35]
e[60]
Fig. 1 Prevalence and Acquisition of MRSA colonization by quarter during the study period (Jan 2009–Dec 2010). The graph shows the number
of screened patients at admission and at discharge, MRSA colonization rate at admission, and MRSA acquisition rate at discharge
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prevalence rates for ward A, B & C were 12.7, 12.2 and
11.3 % respectively throughout the study period. Univar-
iate analyses of demographic and admission data of all
screening episodes are summarized in Table 4. The me-
dian age of those who screened positive at admission
was 61 versus 46 years for those who screened negative
(p < 0.001). In those aged 65 years and above, the odds
of colonization were 3.91 times greater than those less
than 65 years of age (p < 0.001). Male patients were less
likely to be colonized with MRSA at admission than fe-
males (odds ratio [OR], 0.74; 95 % confidence interval
[CI], 0.57–0.98; p = 0.03).
In the univariate analyses, patients colonized with
MRSA on admission tended to be Chinese (OR, 1.36;
95 % CI, 1.00–1.86; p = 0.04). ID patients were less likely
to test positive for MRSA on admission than HIV pa-
tients and dermatological patients (OR 0.16; 95 % CI,
0.08–0.27; p < 0.001); the opposite was true for dermato-
logical patients (OR 2.91; 95 % CI, 2.23–3.81; p < 0.001).
The multivariate analysis showed that patients with
older age (adjusted OR [aOR] 1.03; 95 % CI, 1.02–1.04;
p < 0.001) and dermatological patient status (aOR 1.49;
95 % CI, 1.11–1.20; p = 0.008) had higher risk of MRSA
colonization at admission, while patients with other infec-
tious diseases (aOR 0.27; 95 % CI, 0.15–0.48; p < 0.001)
had decreased colonization risk (Table 5).
Of 1984 patient admissions with MRSA negative on
entry, 1767 screenings involving 1357 patients were
done at discharge (excluding 130 patient admissions that
refused to do screening at exit and 87 patient admissions
that discharged/transferred within 48 h after admission).
Of these, 85 screening episodes (4.8 %) were MRSA
positive. MRSA acquisition rates for ward A, B & C were
8.0, 4.8 and 3.2 % respectively during the study period
(Table 6). Patients who acquired MRSA during
hospitalization were more likely to be older than those
who were negative (median age 55 vs. 46 years, respect-
ively; p < 0.001). Gender and ethnicity were not statisti-
cally significant factors for MRSA acquisition.
The duration of hospital stay was longer for patients
who acquired MRSA compared to patients who did not
(OR 1.04; 95 % CI, 1.02–1.06; p < 0.001). ID patients
were less likely to acquire MRSA than HIV patients and
dermatological patients (OR 0.24; 95 % CI, 0.09–0.53;
p = 0.0001). Conversely, MRSA acquisition was more
likely to occur in dermatological patients compared to
HIV patients and ID patients (OR 2.25; 95 % CI, 1.42–5.39;
p = 0.0002). MRSA acquisition was not associated with
ward layout (OR 0.95; 95 % CI, 0.58–1.62).
The multivariate analysis showed that age (aOR 1.02;
95 % CI, 1.01–1.03; p = 0.002) and length of stay (aOR
1.04; 95 % CI, 1.03–1.06; p < 0.001) were predictors of
MRSA acquisition. Compared to dermatological and
HIV patients, ID patients were less likely to acquire
MRSA during hospital stay (aOR, 0.25; 95 % CI, 0.11–0.60;
p = 0.002) (Table 7).
Economic and disease burden
For the study period 2009–2010, the total hospitalization
direct cost for all patients was estimated to be $103,869.
Table 4 Univariate analysis of demographic and admission data of entry screening (n = 2257)
MRSA positive on admission,
[n = 273 (%)a]
MRSA negative on admission,
[n = 1984 (%)a]
OR (95 % CI) p value
Demographics
Age, median (range) 61 (18–97) 46 (13–109) 1.04 (1.03–1.05) <0.001
≥ 65 years 118 (43.2) 323 (16.3) 3.91 (2.96–5.16) <0.001
< 65 years 155 (56.8) 1661 (83.7) 1.0
Gender
Male 178 (65.2) 1420 (71.6) 0.74 (0.57–0.98) 0.03
Female 95 (34.8) 564 (28.4) 1.0
Ethnicity
Chinese 210 (76.9) 1410 (71.1) 1.36 (1.00–1.86) 0.04
Malay 35 (12.8) 238 (12.0) 1.08 (0.72–1.58) 0.70
Indian 19 (7.0) 181 (9.1) 0.74 (0.43–1.22) 0.24
Others 9 (3.3) 155 (7.8) 0.40 (0.18–0.80) 0.007
Patient groups
HIV 97 (35.5) 816 (41.1) 0.79 (0.60–1.03) 0.077
Dermatology 162 (59.3) 662 (33.4) 2.91 (2.23–3.81) <0.001
Infectious disease 14 (5.1) 506 (25.5) 0.16 (0.08–0.27) <0.001
aUnless otherwise indicated
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This cost was divided between hospitalization cost of
$4469 for ID patients, $63,277 for dermatological patients,
and $36,123 for HIV patients, based on hospitalization of
four days for HIV and ID patients and three days for der-
matological patients with MRSA acquisition. On average,
the daily hospital bill of dermatological patients ($372)
was higher than that of the ID ($228) and HIV patients
($266). The total value of productivity loss for MRSA pa-
tients was estimated at $50,453. The productivity loss for
HIV, dermatological and ID patients was $21,049, $26,366
and $3038, respectively.
The total cost of the program was $129,916. Costs of
cleaning positive rooms, collating data, swabbing and
hand rub bottles used were estimated at $738, $2203,
$11,035 and $15,502 respectively. The screening cost
paid per patient is $25, leading to a total screening cost
of $100,439.
By weighing the costs of the screening program against
the direct costs that can be avoided as a result of imple-
menting the program, the results show that the program
costs are 1.3 times higher than the avoided direct costs,
while if we weigh the program costs against the avoided
direct and indirect costs, we will find that the avoided
total costs are 1.1 times higher than the program costs.
The cost-effectiveness ratio (CER) was estimated to be
−400 $/DALY averted (and −428 $ per infection pre-
vented), and estimated at −197, 3949, and −663 $/DALY
averted for HIV, ID and dermatological patients, respect-
ively. Using the Singaporean per capita gross national in-
come of $55,183 as the cost-effectiveness threshold [36],
we find that the isolation and screening program is cost
saving as it is less than this threshold and with a negative
value, implying that the interventional program is not only
economically justified but gains could also be expected
from implementing this program.
Uncertainty analysis
In order to investigate the robustness of the estimated
impacts and the effectiveness of the screening program,
Monte-Carlo simulations (1000 iterations) were con-
ducted to account for uncertainty in the percentage of
Table 5 Multivariate analysis of independent risk factors
associated with MRSA colonization at admission
Risk factor Coefficient Adjusted OR (95 % CI) p value
Age (per year of increase) 0.022 1.03 (1.02–1.04) <0.001
Dermatological patients 0.367 1.49 (1.11–1.20) 0.008
ID patients −1.325 0.27 (0.15–0.48) <0.001
Table 6 Univariate analysis of demographic and admission data on acquisition (n = 1767)
Acquired MRSA,
[n = 85 (%)a]
Did not acquire MRSA,
[n = 1682 (%)a]
OR (95 % CI) p value
Demographics
Age, median (range) 55 (15–109) 46 (13–109) 1.03 (1.01–1.04) <0.001
≥ 65 years 28 (32.9) 273 (16.2) 2.53 (1.52–4.14) <0.001
< 65 years 57 (67.1) 1409 (83.8) 1.0
Gender
Male 59 (69.4) 1180 (70.2) 0.96 (0.59–1.62) 0.88
Female 26 (30.6) 502 (29.8) 1.0
Ethnicity
Chinese 63 (74.1) 1197 (71.2) 1.2 (0.69–2.00) 0.56
Malay 9 (10.6) 202 (12.0) 0.87 (0.38–1.77) 0.69
Indian 7 (8.2) 157 (9.3) 0.87 (0.33–1.93) 0.73
Others 6 (7.1) 126 (7.5) 0.94 (0.33–2.19) 0.88
Patient groups
HIV 32 (37.7) 647 (38.5) 0.97 (0.60–1.54) 0.880
Dermatology 46 (54.1) 578 (34.4) 2.25 (1.42–5.39) 0.0002
Infectious disease 7 (8.2) 457 (27.2) 0.24 (0.09–0.53) 0.0001
Admission ward
Single-bed room 61 (71.8) 1223 (72.7) 0.95 (0.58–1.62) 0.849
Multi-bed room 24 (28.2) 459 (27.3) 1.0
Length of stay, days; median (range) 8 (2–105) 5 (1–145) 1.04 (1.02–1.06) <0.001
a Unless otherwise indicated
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colonized patients who develop infection (triangular dis-
tribution of 0.11, 0.35, 0.60) [37–39], the disability
weights used in DALYs calculation (i.e. triangular distri-
bution of 0.041, 0.07, 0.65), and the estimated effective-
ness of the program which is determined from the
selected duration of our on-going study (i.e. triangular
distribution of one, two and three quarters).
The results showed that the estimated mean and
standard deviation of the cost-effectiveness were −198
and 148 $/DALY averted, while the 5th and 95th percen-
tiles were estimated at −441 and 15 $/DALY averted
(Fig. 2).
Discussion
This study is different from previously published studies
because it took place in a unique setting which houses
only patients with infectious diseases and/or dermatology
inpatients. The screening program was rolled out with the
administrative decision of screening only HIV patients in
ward A as the length of stay for general infectious disease
cases was short with an average of 2–4 days. Screening of
HIV patients with longer hospital stay allowed studying
the epidemiology and risk factors for MRSA acquisition in
this specific patient population.
A previous study done at two general hospitals in
Singapore by Pada et al. [27] found that inpatient cases
with clinically significant healthcare-associated MRSA
infections were less likely to be of Chinese ethnicity
compared to non-infected controls. However, the reverse
is true for colonization as we found in this study that
among different ethnic groups, patients with Chinese
origin were more likely to have colonized with MRSA
upon screening on admission than patients of non-
Chinese origins in univariate analysis. Further study is
required to verify the previous finding in our setting.
We also found that elderly patients and dermatological
patients had a higher prevalence of MRSA colonization.
Our findings are consistent with other studies which
showed that patients with skin lesions and elderly patients
had higher chances of MRSA carriage on hospital admis-
sion [10, 28]. It is not impossible that the high prevalence
of MRSA colonization in dermatological patients in this
study reflects community-associated (CA-MRSA) or that
those with skin lesions are at higher risk of contracting
MRSA. We noted studies in Singapore reported increasing
trend of CA-MRSA cases in Singapore [40, 41].
It has been shown that the presence of chronic skin
breaks is significantly associated with MRSA acquisition
[42, 43]. In this study, we do not know if all patients ad-
mitted for skin diseases had chronic skin breaks. In order
to explain why ID patients were less likely to screen posi-
tive at admission, we observed that dermatological pa-
tients were older than ID patients (median age 72 vs.
49 years, respectively).
We also found that longer hospital length of stay was
an independent predictor of MRSA acquisition. This re-
sult confirmed previous findings where length of stay
was a predictor of MRSA acquisition both in the general
wards and the intensive care unit [44–46]. This may be
an indicator that patients with more severe underlying
diseases may require longer stays in the hospital, and
Table 7 Multivariate analysis of independent risk factors
associated with MRSA acquisition
Risk factor Coefficient Adjusted OR
(95 % CI)
p value
Age (per year of increase) 0.016 1.02 (1.01–1.03) 0.002
Length of stay (per day of
increase)
0.042 1.04 (1.03–1.06) <0.001
ID patients −1.208 0.25 (0.11–0.60) 0.002
Fig. 2 Cumulative distribution of the cost-effectiveness of the screening program. The results showed that the estimated mean and standard deviation
of the cost-effectiveness were −198 and 148 $/DALY averted, while the 5th and 95th percentiles were estimated at −441 and 15 $/DALY averted
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these long stayers likely need increased nursing care re-
quirements. It has been shown that multiresistant
micro-organisms have been isolated from the hands,
gloves, aprons, and other instruments used by healthcare
workers engaged in the care of patients who are colo-
nized or infected by these organisms [47]. Though there
is not likely to be a single solution for MRSA control,
hand hygiene is vital and the most basic measure among
several elements to help prevent the spread of MRSA.
Despite recent infection control activities such as hand
hygiene campaigns and implementation of hand hygiene
audits [48], the finding that MRSA acquisition at CDC
does occur highlights the need to review nursing work-
loads, adequate staffing resources, and adherence to in-
fection control practices.
This study is the first to our knowledge that evaluates
the cost-effectiveness of screening and isolation of
MRSA patients in a tropical country. Another unique
feature of the analysis is the evaluation of acquisition
rates among specific types of patients (dermatological,
HIV and infectious disease patients) and the comparison
of the cost-effectiveness of screening and isolation be-
tween them, showing that marked differences exist be-
tween patient types. This is due to a combination of risk
factors and length of hospital stay that affect the cost
and disease profile of the patients.
Our results point towards high MRSA prevalence that
can be cost-effectively reduced by selective screening
and isolation programs in pre-selected subpopulations in
Singapore. On average the CER was estimated at −400
$/DALY averted. The screening program was cost saving
for HIV patients (−197 $/DALY), dermatological pa-
tients (−663 $/DALY) and cost effective for ID patients
(3949 $/DALY), respectively. Our findings thus demon-
strate that screening and isolation of patients can be
highly cost-effective in a tropical setting. These findings
are specific to the high indirect costs associated to job
absenteeism and high hospitalization costs in Singapore.
These results, nonetheless, would offer insights in other
tropical countries that are increasingly approaching high-
income status such as Brazil or Malaysia and which pre-
sumably would present similar prevalence levels for
MRSA. Our results could also be extrapolated to other
specialized hospital settings dealing with HIV and derma-
tological patients, offering insights on isolation and
screening strategies.
Pereira et al. examined MRSA control activities in
Singapore and found that isolation policies and screen-
ing practices were inconsistent among health care insti-
tutions [49]. Universal screening coupled with isolation
and decolonization of patients has been identified as the
most effective interventions in mathematical models
[50]. In our setting, MRSA-positive patients might have
been a potential source of spread if we did not practice
isolation for those who tested positive during initial
screening.
Studies assuring the effectiveness of universal screening
in decreasing MRSA prevalence showed that there was a
substantial reduction in MRSA infections with screening
and decolonization [6, 51]. Nonetheless, resource implica-
tion would be an issue for universal screening with isola-
tion and decolonization. As such, selective screening
strategies could detect colonized patients who are at risk
to reduce the current prevalent and acquisition rates in
hospitals, and it could spare other patients from the bur-
den of serious infection. Active MRSA selective screening
followed by appropriate infection control practices has
been shown to be successful in reducing acquisition rates
in hospitals. Such strategies have been incorporated into
many institutionalized MRSA control programs [52–54].
The effectiveness of isolation measures in reducing the in-
cidence of MRSA colonization and infection in hospital
inpatients is however not yet quantitatively strong, due to
lack of consideration of confounders and appropriate stat-
istical analyses [55]. In addition, there is not yet consensus
about the optimal screening strategy and the course of ac-
tion once MRSA infected patients are detected [56], ran-
ging from routine decolonization of all carriers in Denmark
and the Netherlands to only particularly transmissible or
virulent MRSA clones being decolonized in Western
Australia [57].
In the present study, MRSA carriage rate on hospital
admission in this patient population was 12 %. This high
rate of MRSA colonization is alarming because the
chances of developing an invasive infection are high
once a patient is colonized [33, 38, 58].
There are limitations to our study. Our findings may
not be nationally representative as the screening pro-
gram was done only in one institution that houses pa-
tients with specific medical conditions. Our screening
policy needs the capacity to strictly isolate or cohort pa-
tients which might not be feasible at a setting where
there is limited availability of isolation facilities. We also
acknowledge that in our study, 4 % of patient admissions
with unknown MRSA history were not screened on ad-
mission and this will affect MRSA colonization pressure
in the ward. Our hospital started hand hygiene audits in
the year of 2010, thus we failed to include this in our
current study. Additionally, we did not look at co-
morbidities or other risk factors for MRSA colonization
or acquisition such as health seeking behavior, previous
hospitalization history and recent antibiotic usage as the
data reported here were gathered for operational pur-
poses. Moreover, regarding the estimation of economic
burden of the disease, we could not account for some
costs such as microbiology lab material and additional
costs to isolate detected MRSA patients who would have
otherwise remained in less costly multiple bed rooms.
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Missing information on the prevalence of MRSA before
implementing the screening program and using instead
the first quarter of our study as a surrogate for the base-
line without the screening program was a limiting factor
in our CEA. The robustness of this assumption was con-
sidered in the uncertainty analysis in the estimated effect-
iveness rate of the program by varying the selected
duration to from one to two and three quarters, showing
that our results are robust to this assumption.
Despite these limitations, a number of practical issues
were identified. High prevalence and acquisition of MRSA
within this center reinforces the need for MRSA preven-
tion and control, and increased hand hygiene compliance.
Resource utilization would be an issue for universal
screening or sustaining selected screening of MRSA in the
long run. However, this study demonstrated the cost-
effectiveness of selected screening and isolation, which
strongly favors the continuation of such efforts. More clin-
ical research is needed to understand the risk factors for
MRSA acquisition during hospitalization and the utility of
molecular epidemiology of MRSA to study the spread of
MRSA, including the interplay between hospital and com-
munity MRSA.
Conclusions
Overall our results indicate high MRSA prevalence that
can be cost effectively reduced by selectivescreening and
isolation programs in Singapore.
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